BioCentury
ARTICLE | Clinical News

FDA approves Imbruvica to treat chronic GvHD

August 4, 2017 7:50 PM UTC

FDA approved Imbruvica ibrutinib (PCI-32765) from AbbVie Inc. (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) to treat adults with chronic graft-versus-host-disease (GvHD) after failure of ≥1 lines of systemic therapy. The agency said Imbruvica is the first FDA-approved therapy to treat chronic GvHD.

FDA based the approval on data from the Phase Ib/II PCYC-1129 trial in which Imbruvica led to an overall response rate (ORR) of 67% in 42 evaluable GvHD patients who failed prior systemic therapy (see BioCentury, Dec. 9, 2016)...

BCIQ Company Profiles

AbbVie Inc.

Johnson & Johnson

BCIQ Target Profiles

Bruton's tyrosine kinase (Btk)